



AROA BIOSURGERY TO PRESENT AT NWR VIRTUAL INVESTOR CONFERENCE

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, 'Aroa' or the 'Company') is pleased to announce CEO Brian Ward and CFO James Agnew will deliver an investor presentation at the NWR Virtual Investor Conference to be held on Thursday 5 November.

Presentation time: 11:20am AEDT Thursday 5 November 2020

Attend online: Investors and interested parties can register for the presentation via the following link:

https://us02web.zoom.us/webinar/register/WN_7HRn-vTIRKWmBc1p_zsyjQ

Investors are invited to submit questions prior to the event to matt@nwrcommunications.com.au

More information can be found at <http://nwrconference.webflow.io>

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery

Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Committed to 'unlocking regenerative healing for everybody', its products are developed from the Company's proprietary Endoform® technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Clinically proven with peer reviewed publications, Aroa's products have been used in more than four million procedures to date, with distribution into its key market of the United States by Appulse and Tela Bio.

Founded in 2008, Aroa is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). www.aroabio.com/

Contacts

Investor Relations

Simon Hinsley

Investor Relations

shinsley@aroabio.com

+ 61 401 809 653

Media

Australia

Matthew Wright

matt@nwrcommunications.com.au

+61 451 896 420

New Zealand

Piet De Jong

piet.dejong@baldwinboyle.com

+64 21 812 766